Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))

Samir Mehndiratta, Mei Hsiang Lin, Yi Wen Wu, Chun Han Chen, Tung Yun Wu, Kuo Hsiang Chuang, Min Wu Chao, Yi Ying Chen, Shiow Lin Pan, Mei Chuan Chen, Jing Ping Liou

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret that the information of the second corresponding author (M.-C. Chen) in the affiliation and the footnote of pdf version was misplaced. The correct version should be: Mei-Chuan Chena,h∗∗ h Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taiwan. ∗∗Corresponding author. Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taiwan. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Article number112406
JournalEuropean Journal of Medicinal Chemistry
Volume199
DOIs
Publication statusPublished - Aug 1 2020

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))'. Together they form a unique fingerprint.

Cite this